Recombinant human CCL2 induces dose-dependent prostate cancer cell proliferation in vitro and this pro-growth function is accomplished by the activation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway (15,16). This evidence concerns the gene AKT1 and prostate cancer.